GV1001, an hTERT-Derived Peptide, Prevents Cisplatin-Induced Nephrotoxicity by Preserving Mitochondrial Function
Cells · 2025
DOI: 10.3390/cells14221818 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Wei Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Shapiro Family Laboratory of Viral Oncology and Aging Research, UCLA School of Dentistry, 714 Tiverton Ave, Los Angeles, CA 90095, USA. Hauptthemen laut MEDLINE: Cisplatin, Mitochondria, Kidney, Peptide Fragments. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDCR NIH HHS, NIH HHS, UCLA.
Abstract (Originalsprache)
GV1001, a multifunctional peptide, has shown numerous biomedical activities, including antioxidant, anti-inflammatory, anti-Alzheimer’s, and anti-atherosclerotic effects, and protects mitochondria from cytotoxic agents. Cisplatin is a widely used chemotherapeutic agent against cancers, but its clinical utility is limited by nephrotoxicity driven by mitochondrial dysfunction in renal epithelial cells. Here, we investigated whether GV1001 protected against cisplatin-induced nephrotoxicity (CIN) in vivo and preserved mitochondrial integrity in human renal epithelial cells in vitro. In mice, GV1001 substantially mitigated CIN by significantly reducing histological damage, kidney injury marker expression, macrophage infiltration, endothelial-to-mesenchymal transition, inflammation, and apoptosis. In cultured renal epithelial cells, GV1001 maintained mitochondrial membrane potential, preserved ATP production, and prevented mitochondrial membrane peroxidation possibly by binding to cardiolipin. GV1001 also reduced the level of reactive oxygen species (ROS), suppressed cytochrome c release into the cytosol, and inhibited activation of apoptosis-related pathways elicited by cisplatin. Collectively, these findings demonstrated that GV1001 might protect kidney from cisplatin through maintaining mitochondrial structure and function and suppressing downstream injury cascades in renal epithelial cells. By directly targeting the mitochondrial mechanisms underlying cisplatin toxicity, GV1001 represents as a promising therapeutic strategy to mitigate CIN and improve the safety of cisplatin-based chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Shapiro Family Laboratory of Viral Oncology and Aging Research, UCLA School of Dentistry, 714 Tiverton Ave, Los Angeles, CA 90095, USA.
- UCLA Jonsson Comprehensive Cancer Center, 10833 Le Conte Ave, Los Angeles, CA 90095, USA.
- Teloid Inc., 3580 Wilshire Blvd, Los Angeles, CA 90024, USA.
- Department of Medicine, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA 90095, USA.
ORCID-Profile: No-Hee Park
Förderung
- NIDCR NIH HHS
- NIH HHS
- UCLA
- Various Donors Fund
- UCLA Chancellor’s Office
- various private donations
- National Institute of Dental Research
Zitieren
APA
Chen, W., Beheshtian, C., Kim, S., Kim, R., Kim, S., & Park, N. H. (2025). GV1001, an hTERT-Derived Peptide, Prevents Cisplatin-Induced Nephrotoxicity by Preserving Mitochondrial Function. Cells. https://doi.org/10.3390/cells14221818
Vancouver
Chen W, Beheshtian C, Kim S, Kim R, Kim S, Park NH. GV1001, an hTERT-Derived Peptide, Prevents Cisplatin-Induced Nephrotoxicity by Preserving Mitochondrial Function. Cells. 2025. doi:10.3390/cells14221818
BibTeX
@article{Chen2025,
author = {Chen, Wei and Beheshtian, Cheyenne and Kim, Seojin and Kim, Reuben and Kim, Sangjae and Park, No-Hee},
title = {GV1001, an hTERT-Derived Peptide, Prevents Cisplatin-Induced Nephrotoxicity by Preserving Mitochondrial Function},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14221818}
}
EUVIMED